Citadel Advisors’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-97,726
| Closed | -$1.97M | – | 14321 |
|
|
2026
Q1 | $1.97M | Buy |
97,726
+59,965
| +159% | +$966K | ﹤0.01% | 6090 |
|
|
2025
Q4 | $610K | Buy |
+37,761
| New | +$500K | ﹤0.01% | 8558 |
|
|
2025
Q3 | – | Sell |
-15,841
| Closed | -$179K | – | 13473 |
|
|
2025
Q2 | $179K | Buy |
+15,841
| New | +$194K | ﹤0.01% | 10784 |
|
|
2025
Q1 | – | Sell |
-136,493
| Closed | -$1.39M | – | 15057 |
|
|
2024
Q4 | $1.16M | Buy |
136,493
+9,244
| +7% | +$95.7K | ﹤0.01% | 6723 |
|
|
2024
Q3 | $1.47M | Buy |
127,249
+108,427
| +576% | +$1.36M | ﹤0.01% | 6089 |
|
|
2024
Q2 | $222K | Sell |
18,822
-68,262
| -78% | -$797K | ﹤0.01% | 9704 |
|
|
2024
Q1 | $1.03M | Sell |
87,084
-696,614
| -89% | -$9.29M | ﹤0.01% | 6847 |
|
|
2023
Q4 | $9.6M | Sell |
783,698
-144,804
| -16% | -$1.32M | ﹤0.01% | 2903 |
|
|
2023
Q3 | $8.94M | Buy |
928,502
+81,896
| +10% | +$837K | ﹤0.01% | 2830 |
|
|
2023
Q2 | $7.62M | Buy |
846,606
+718,211
| +559% | +$6.62M | ﹤0.01% | 3042 |
|
|
2023
Q1 | $1.01M | Buy |
128,395
+26,868
| +26% | +$200K | ﹤0.01% | 6765 |
|
|
2022
Q4 | $686K | Sell |
101,527
-37,995
| -27% | -$204K | ﹤0.01% | 7581 |
|
|
2022
Q3 | $2.02M | Sell |
139,522
-33,759
| -19% | -$472K | ﹤0.01% | 5557 |
|
|
2022
Q2 | $1.71M | Buy |
173,281
+110,311
| +175% | +$1.22M | ﹤0.01% | 5873 |
|
|
2022
Q1 | $928K | Buy |
62,970
+45,564
| +262% | +$655K | ﹤0.01% | 7877 |
|
|
2021
Q4 | $230K | Sell |
17,406
-23,256
| -57% | -$370K | ﹤0.01% | 11558 |
|
|
2021
Q3 | $710K | Sell |
40,662
-35,186
| -46% | -$713K | ﹤0.01% | 9035 |
|
|
2021
Q2 | $1.82M | Buy |
75,848
+30,437
| +67% | +$796K | ﹤0.01% | 6839 |
|
|
2021
Q1 | $1.17M | Buy |
+45,411
| New | +$1.19M | ﹤0.01% | 7715 |
|
|
2020
Q2 | – | Sell |
-93,503
| Closed | -$715K | – | 10174 |
|
|
2020
Q1 | $715K | Buy |
+93,503
| New | +$1.26M | ﹤0.01% | 5894 |
|
|
2019
Q4 | – | Sell |
-10,194
| Closed | -$118K | – | 9434 |
|
|
2019
Q3 | $118K | Sell |
10,194
-10,878
| -52% | -$176K | ﹤0.01% | 8406 |
|
|
2019
Q2 | $467K | Buy |
+21,072
| New | +$494K | ﹤0.01% | 6925 |
|
|
2016
Q3 | – | Sell |
-1,923
| Closed | -$18K | – | 7490 |
|
|
2016
Q2 | $18K | Buy |
+1,923
| New | +$22.3K | ﹤0.01% | 6645 |
|
|
2015
Q3 | – | Sell |
-279
| Closed | -$28K | – | 9065 |
|
|
2015
Q2 | $28K | Buy |
+279
| New | +$27.7K | ﹤0.01% | 7996 |
|
Other funds holding KALV
Citadel Advisors's KALV Position: Q2 2026 in Review
Citadel Advisors sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 97,726 shares — an estimated $1.97M sold.
Citadel Advisors first reported a position in KALV in Q2 2015 and held it in 24 quarters. The position peaked at $9.6M in Q4 2023. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Citadel Advisors reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 97,726 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.97M.
- Citadel Advisors first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 24 quarters.
- Citadel Advisors's KalVista Pharmaceuticals position peaked at $9.6M in Q4 2023.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.